Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of cisplatin plus metronomic cyclophosphamide in previously treated advanced triple-negative breast cancer
2010-020835-38Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and cyclophosphamide in triple-negative breast cancer (TNBC), sponsored by European Institute of Oncology. Primary endpoint: Objective response rate. Started Jan 2012; status: completed.
02
Drugs
cisplatincyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2010-020835-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020835-38.